New drug duo aims to shrink lung tumors before surgery

NCT ID NCT07256509

Not yet recruiting Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding SYS6010 to the standard drug osimertinib before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutant non-squamous non-small cell lung cancer). About 120 participants with stage II-IIIB disease will receive either the combination or osimertinib alone before their tumor is removed. The main goals are to see how many tumors shrink or disappear completely after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6010 combined with osimertinib
What this could lead to: If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with EGFR-mutant lung cancer.
What could go wrong: This is an early Phase 2 trial with only 120 participants. The combination may not work better than osimertinib alone, and side effects from adding SYS6010 are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.